Cost of antimicrobial resistance in healthcare settings: A critical review

Issues in Infectious Diseases

Volumn 6, Issue , 2010, Pages 102-119

  Merz, Liana R ^a,c   Guth, Rebecca M ^a   Fraser, Victoria J ^a,b  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BARNES JEWISH HOSPITAL   (United States)

^c BJC HEALTHCARE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84870015276     PISSN: 16601890     EISSN: 16623819     Source Type: Book Series    
DOI: 10.1159/000298759     Document Type: Review

References (46)

1. Hidron AI, Edwards JR, Patel J, et al: NHSN annual update: antimicrobial-resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008;29:996-1011.
2. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485.
3. Centers for Disease Control and Prevention. Campaign to prevent antimicrobial resistance in healthcare settings. 2002. http://www.cdc.gov/drug resistance/healthcare/problem.htm
4. McHugh CG, Riley LW: Risk factors and costs associated with methicillin-resistant Staphylococcus aureus bloodstream infections. Infect Control Hosp Epidemiol 2004;25:425-430. (Pubitemid 38621091)
5. Carmeli Y, Eliopoulos G, Mozaffari E, Samore M: Health and economic outcomes of vancomycinresistant Enterococci. Arch Intern Med 2002;162:2223-2228. (Pubitemid 35231592)
6. Carmeli Y, Troillet N, Karchmer AW, Samore MH: Health and economic outcomes of antibiotic resistance in Pseudomonas aeruginosa. Arch Intern Med 1999;159:1127-1132. (Pubitemid 29230866)
7. Cosgrove SE, Carmeli Y: The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis 2003;36:1433-1437. (Pubitemid 36702878)
8. Cosgrove SE, Kaye KS, Eliopoulous GM, Carmeli Y: Health and economic outcomes of the emergence of third-generation cephalosporin resistance in Enterobacter species. Arch Intern Med 2002;162:185-190. (Pubitemid 34098188)
9. Engemann JJ, Carmeli Y, Cosgrove SE, et al: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598. (Pubitemid 36259564)
10. Office of Technology A: Impacts of antibiotic-resistant bacteria. Washington, US Government Printing Office, 1995. Report No. OTA-H-629.
11. Howard D, Cordell R, McGowan JE Jr, Packard RM, Scott RD, Solomon SL: Measuring the economic costs of antimicrobial resistance in hospital settings: summary of the Centers for Disease Control and Prevention Emory Workshop. Clin Infect Dis 2001;33:1573-1578. (Pubitemid 34246154)
12. Wakefield DS, Helms CM, Massanari RM, Mori M, Pfaller M: Cost of nosocomial infection: relative contributions of laboratory, antibiotic, and per diem costs in serious Staphylococcus aureus infections. Am J Infect Control 1988;16:185-192.
13. Rubin RJ, Harrington CA, Poon A, Dietrich K, Greene JA, Moiduddin A: The economic impact of Staphylococcus aureus infection in New York City hospitals. Emerg Infect Dis 1999;5:9-17. (Pubitemid 29124770)
14. Kim T, Oh PI, Simor AE. The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104. (Pubitemid 32157160)
15. Gertman PM, Restuccia JD: The appropriateness evaluation protocol: a technique for assessing unnecessary days of hospital care. Med Care 1981;19:855-871. (Pubitemid 11021292)
16. Capitano B, Leshem OA, Nightingale CH, Nicolau DP: Cost effect of managing methicillin-resistant Staphylococcus aureus in a long-term care facility. J Am Geriatr Soc 2003;51:10-16. (Pubitemid 36119928)
17. Hollenbeak CS, Murphy D, Dunagan WC, Fraser VJ: Nonrandom selection and the attributable cost of surgical-site infections. Infect Control Hosp Epidemiol 2002;23:177-182. (Pubitemid 34297270)
18. Abramson MA, Sexton DJ: Nosocomial methicillinresistant and methicillin-susceptible Staphylococcus aureus primary bacteremia: at what costs? Infect Control Hosp Epidemiol 1999;20:408-411.
19. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C: Control of endemic methicillin-resistant Staphylococcus aureus: a cost-benefit analysis in an intensive care unit. JAMA 1999;282:1745-1751. (Pubitemid 29533605)
20. Chaix C, Durand-Zaleski I, Alberti C, Brun-Buisson C: A model to compute the medical cost of patients in intensive care. Pharmacoeconomics 1999;15:573-582. (Pubitemid 29256518)
21. Kopp BJ, Nix DE, Armstrong EP: Clinical and economic analysis of methicillin-susceptible and -resistant Staphylococcus aureus infections. Ann Pharmacother 2004;38:1377-1382. (Pubitemid 39100187)
22. Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y: The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 2005;26:166-174. (Pubitemid 40445022)
23. Reed SD, Friedman JY, Engemann JJ, et al: Costs and outcomes among hemodialysis-dependent patients with methicillin-resistant or methicillinsusceptible Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 2005;26:175-83. (Pubitemid 40445023)
24. Lodise TP, McKinnon PS: Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 2005;52:113-122. (Pubitemid 40826937)
25. Ben-David D, Novikov I, Mermel LA: Are there differences in hospital cost between patients with nosocomial methicillin-resistant Staphylococcus aureus bloodstream infection and those with methicillinsusceptible S. aureus bloodstream infection? Infect Control Hosp Epidemiol 2009;30:453-460.
26. Stosor V, Peterson LR, Postelnick M, Noskin GA: Enterococcus faecium bacteremia: does vancomycin resistance make a difference? Arch Intern Med 1998;158:522-527. (Pubitemid 128681613)
27. Webb M, Riley LW, Roberts RB: Cost of hospitalization for and risk factors associated with vancomycinresistant Enterococcus faecium infection and colonization. Clin Infect Dis 2001;33:445-452. (Pubitemid 32709574)
28. Pelz RK, Lipsett PA, Swoboda SM, et al: Vancomycinsensitive and vancomycin-resistant enterococcal infections in the ICU: attributable costs and outcomes. Intensive Care Med 2002;28:692-697. (Pubitemid 34639479)
29. Song X, Srinivasan A, Plaut D, Perl TM: Effect of nosocomial vancomycin-resistant enterococcal bacteremia on mortality, length of stay, and costs. Infect Control Hosp Epidemiol 2003;24:251-256. (Pubitemid 36538136)
30. Butler AM, Olsen MA, Merz LR, et al: The attributable cost of enterococcal bloodstream infections in a non-surgical hospital cohort. Infect Control Hosp Epidemiol 2009; in Press.
31. Wilson SJ, Knipe CJ, Zieger MJ, et al: Direct costs of multidrug-resistant Acinetobacter baumannii in the burn unit of a public teaching hospital. Am J Infect Control 2004;32:342-344. (Pubitemid 39348964)
32. Harris AD, Samore MH, Lipsitch M, Kaye KS, Perencevich E, Carmeli Y: Control-group selection importance in studies of antimicrobial resistance: examples applied to Pseudomonas aeruginosa, Entero cocci, and Escherichia coli. Clin Infect Dis 2002;34:1558-1563. (Pubitemid 34615439)
33. Engemann JJ, Carmeli Y, Cosgrove SE, et al: Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis 2003;36:592-598. (Pubitemid 36259564)
34. Guideline for isolation precautions in hospitals. Part II. Recommendations for isolation precautions in hospitals. Hospital Infection Control Practices Advisory Committee. Am J Infect Control 1996;24:32-52.
35. Muto CA, Jernigan JA, Ostrowsky BE, et al: SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and enterococcus. Infect Control Hosp Epidemiol 2003;24:362-386. (Pubitemid 36612323)
36. Rubinovitch B, Pittet D: Screening for methicillinresistant Staphylococcus aureus in the endemic hospital: what have we learned? J Hosp Infect 2001;47:9-18.
37. Montecalvo MA, Jarvis WR, Uman J, et al: Costs and savings associated with infection control measures that reduced transmission of vancomycinresistant Enterococci in an endemic setting. Infect Control Hosp Epidemiol 2001;22:437-442. (Pubitemid 32889276)
38. Puzniak LA, Gillespie KN, Leet T, Kollef M, Mundy LM: A cost-benefit analysis of gown use in controlling vancomycin-resistant Enterococcus transmission: is it worth the price? Infect Control Hosp Epidemiol 2004;25:418-424. (Pubitemid 38621090)
39. Tiemersma EW, Bronzwaer SL, Lyytikainen O, et al: Methicillin-resistant Staphylococcus aureus in Europe, 1999-2002. Emerg Infect Dis 2004;10:1627-1634. (Pubitemid 39201515)
40. Vriens M, Blok H, Fluit A, Troelstra A, Van der Werken C, Verhoef J: Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch University Medical Center: a 10-year survey. Eur J Clin Microbiol Infect Dis 2002;21:782-786. (Pubitemid 35435699)
41. Manning WG, Fryback DG, Weinstein MC: Reflecting uncertainty in cost-effectiveness analysis; in Gold MR, Siegel JE, Russell LB, Weinstein MC (eds): Cost-Effectiveness in Health and Medicine. Oxford, Oxford University Press, 1996:247-275.
42. Jernigan JA, Titus MG, Groschel DH, Getchell-White S, Farr BM: Effectiveness of contact isolation during a hospital outbreak of methicillin-resistant Staphylococcus aureus. Am J Epidemiol 1996;143:496-504. (Pubitemid 26085080)
43. Afif W, Huor P, Brassard P, Loo VG: Compliance with methicillin-resistant Staphylococcus aureus precautions in a teaching hospital. Am J Infect Control 2002;30:430-433. (Pubitemid 35316429)
44. McGowan JE Jr: Economic impact of antimicrobial resistance. Emerg Infect Dis 2001;7:286-292.
45. Kim T, Oh PI, Simor AE: The economic impact of methicillin-resistant Staphylococcus aureus in Canadian hospitals. Infect Control Hosp Epidemiol 2001;22:99-104. (Pubitemid 32157160)
46. Stone PW, Gupta A, Loughrey M, et al: Attributable costs and length of stay of an extended-spectrum beta-lactamase-producing Klebsiella pneumoniae outbreak in a neonatal intensive care unit. Infect Control Hosp Epidemiol 2003;24:601-606. (Pubitemid 37039619)